Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares.

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $137 from $122 and keeps an Outperform rating ...

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients ...

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...